FRI0258 Long-term prognosisofpatients with systemic lupus erythematosus-associated pulmonary arterial hypertension: cstar-pah cohort study. (15th June 2017)

• Record Type: Journal Article
• Authors: Qian, J; Li, M; Zhang, X; Wang, Q; Zhao, J; Tian, Z; Zeng, X
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 583
• Page End: 584
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.6718
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: SLE-associated pulmonary arterial hypertension (PAH) is common in Asian countries, and the clinical outcome of patients with SLE-associated PAH is dramatically impaired. Objectives: This study aimed to identify the long-term clinical outcomes and prognostic factors of patients with SLE-associated PAH confirmed by right heart catheterization (RHC). Methods: A multicenter cohort of SLE-associated PAH was established. Baseline and follow-up records were collected. The primary endpoint was death from any cause. The secondary experimental end point was treatment goal achievement (TGA), defined as an integrated outcome. Results: Among the 310 patients enrolled from 14 PAH centers, the median follow-up was 24.0 months. The 1-, 3- and 5-year survival rates were 92.1%, 84.8% and 72.9%, respectively. The 1-, 3- and 5-year TGA rates were 31.5%, 53.6% and 62.7%, respectively.Serositis, 6MWD >380 m and CI ≥2.5 L/min×m 2 were identified as independent prognostic factors of TGA. TGA within 5 years was identified as a factor associated with survival in patients with SLE-associated PAH (Figure 1 ). Conclusions: TGA was associated with the long-term survival, which supports and provides evidence to the treat-to-target strategy in SLE-associated PAH. Early diagnosis, intervention and heart function preservation are priorities for better long-term outcomes. References: Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137:376–87. Chung L, Liu J, Parsons L, Hassoun PM, McGoon M, Badesch DB, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest. 2010;138:1383–94. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151–7. Disclosure of Interest: None declared